The Gut Microbiota in Aging: From Compositional Shifts to Therapeutic Opportunities

Population aging is accelerating worldwide, creating an urgent need to understand biological processes that influence late-life health. The gut microbiota, defined here primarily as the bacterial communities inhabiting the intestine, changes across the lifespan and may contribute to immune, metabolic, neural, and musculoskeletal phenotypes of aging. However, reported age-related microbiota signatures remain heterogeneous, reflecting differences in cohort design, sequencing strategy, functional annotation, and clinical context. In this review, we synthesize evidence from human cohorts, animal models, and mechanistic studies on the bidirectional relationship between host aging and gut microbial remodeling. A central theme is that host factors such as immune senescence, barrier dysfunction, altered gastrointestinal physiology, and medication exposure can drive microbial change. In contrast, microbial products can feed back on aging tissues. We distinguish chronological aging, healthy aging, frailty, exceptional longevity, and age-related diseases, and we evaluate how diet, medication exposure, living environment, geography, and disease burden shape reported microbiota signatures. We further organize microbial functions around metabolite-centered pathways, including short-chain fatty acids, trimethylamine N-oxide, phenylacetylglutamine, bile acids, tryptophan derivatives, and uremic microbial toxins. This framework clarifies when microbial alterations should be interpreted as biomarkers, plausible mediators, or candidate therapeutic targets. Finally, we discuss microbiota-targeted interventions, including diet, prebiotics, probiotics, fecal microbiota transplantation, postbiotics, metabolite-based therapeutics, and phage-based strategies, while emphasizing current limits in causal inference, safety, biomarker validation, and clinical implementation.

Authors

Institutions

Publication Details

Journal
Cytotherapy and Longevity
Published
2026-11-17
DOI
https://doi.org/10.66729/cl202607005
Primary Topic
Gut microbiota and health
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

The Gut Microbiota in Aging: From Compositional Shifts to Therapeutic Opportunities

Zengren Zhao, K. Li, Chenyu Guo, Zhixing Wang
Cytotherapy and Longevity
Gut microbiota and health
article

The Gut Microbiota in Aging: From Compositional Shifts to Therapeutic Opportunities

Zengren Zhao, K. Li, Chenyu Guo, Zhixing Wang
article en

Abstract

Population aging is accelerating worldwide, creating an urgent need to understand biological processes that influence late-life health. The gut microbiota, defined here primarily as the bacterial communities inhabiting the intestine, changes across the lifespan and may contribute to immune, metabolic, neural, and musculoskeletal phenotypes of aging. However, reported age-related microbiota signatures remain heterogeneous, reflecting differences in cohort design, sequencing strategy, functional annotation, and clinical context. In this review, we synthesize evidence from human cohorts, animal models, and mechanistic studies on the bidirectional relationship between host aging and gut microbial remodeling. A central theme is that host factors such as immune senescence, barrier dysfunction, altered gastrointestinal physiology, and medication exposure can drive microbial change. In contrast, microbial products can feed back on aging tissues. We distinguish chronological aging, healthy aging, frailty, exceptional longevity, and age-related diseases, and we evaluate how diet, medication exposure, living environment, geography, and disease burden shape reported microbiota signatures. We further organize microbial functions around metabolite-centered pathways, including short-chain fatty acids, trimethylamine N-oxide, phenylacetylglutamine, bile acids, tryptophan derivatives, and uremic microbial toxins. This framework clarifies when microbial alterations should be interpreted as biomarkers, plausible mediators, or candidate therapeutic targets. Finally, we discuss microbiota-targeted interventions, including diet, prebiotics, probiotics, fecal microbiota transplantation, postbiotics, metabolite-based therapeutics, and phage-based strategies, while emphasizing current limits in causal inference, safety, biomarker validation, and clinical implementation.

Cytotherapy and LongevityVol. 1(2)
Hebei Medical University (CN), First Affiliated Hospital of Hebei Medical University (CN)
Gut microbiota and health
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon